23b) Interesting #RCT compared with placebo show the evidence behind this recommendation is only “moderate” in terms of mortality and doubling of SCr. See 🔓https://t.co/oHTWaVeQvG
37) In meta-analyses, individualized maximization of the dose of the ACEi or ARB is associated with 22% ⬇️mortality in patients with #T2D against standard doses. https://t.co/PkcJhZocDP https://t.co/cANNkpXWIQ
23b) Interesting #RCT compared with placebo show the evidence behind this recommendation is only “moderate” in terms of mortality and doubling of SCr. See 🔓https://t.co/QI1urkPJYh https://t.co/ExR1zDB5hJ
37) In meta-analyses, individualized maximization of the dose of the ACEi or ARB is associated with 22% ⬇️mortality in patients with #T2D against standard doses. https://t.co/U4ppy1P4bZ https://t.co/MMWDhA4x8F
37) In meta-analyses, individualized maximization of the dose of the ACEi or ARB is associated with 22% ⬇️mortality in patients with #T2D against standard doses. https://t.co/U4ppy1P4bZ https://t.co/U5K6IMsUKk